ArticleJournal of clinical microbiology2014
Recurrent melioidosis in the Darwin Prospective Melioidosis Study: improving therapies mean that relapse cases are now rare.
Article in Journal of clinical microbiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Omitting the Eradication Phase of Treatment of Adults with Melioidosis: A Pilot, Single-Center Randomized Controlled Trial.Open forum infectious diseases · 2026Article
- Evolutionary Convergence on a Dihydrofolate Reductase Mutation Drives Trimethoprim-Sulfamethoxazole Resistance in Burkholderia thailandensis.ACS infectious diseases · 2026Article
- Melioidosis imported to Northern Germany: a case report series.Infection · 2026Article
- Comparative genomic analysis of paired clinical isolates from a patient with recurrent melioidosis reveals a low within-host mutation rate.Journal of medical microbiology · 2025Article
- PepSeq as a highly multiplexed platform for melioidosis antigen discovery and vaccine development.Frontiers in immunology · 2025Article
- A molecular epidemiological analysis of Burkholderia pseudomallei in southern Thailand.PLoS neglected tropical diseases · 2024Article
- Layering vaccination with antibiotic therapy results in protection and clearance ofInfection and immunity · 2024Article
- Antibiotic susceptibility of clinicalAntimicrobial agents and chemotherapy · 2023Article
- Effective Therapeutic Options for Melioidosis: Antibiotics versus Phage Therapy.Pathogens (Basel, Switzerland) · 2022Review
- The Emergence of Travel-related Infections in Critical Care Units.Journal of translational internal medicine · 2022Article
- Efficacy of Co-Trimoxazole against Experimental Melioidosis Acquired by Different Routes of Infection.Antimicrobial agents and chemotherapy · 2022Article
- The Epidemiology of Melioidosis and Its Association with Diabetes Mellitus: A Systematic Review and Meta-Analysis.Pathogens (Basel, Switzerland) · 2022Article
- Drug screening to identify compounds to act as co-therapies for the treatment of Burkholderia species.PloS one · 2021Article
- Emergence of Burkholderia pseudomallei Sequence Type 562, Northern Australia.Emerging infectious diseases · 2021Article
- 2020 Review and revision of the 2015 Darwin melioidosis treatment guideline; paradigm drift not shift.PLoS neglected tropical diseases · 2020Review
- Human Melioidosis.Clinical microbiology reviews · 2020Review
- Modelling population dynamics and seasonal movement to assess and predict the burden of melioidosis.PLoS neglected tropical diseases · 2019Article
- Extracellular DNA facilitates bacterial adhesion during Burkholderia pseudomallei biofilm formation.PloS one · 2019Article
- Factors affecting clinical outcomes in the management of melioidosis in Singapore: a 16-year case series.BMC infectious diseases · 2018Article
- Virulence of the Melioidosis Pathogen Burkholderia pseudomallei Requires the Oxidoreductase Membrane Protein DsbB.Infection and immunity · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Darwin Prospective Melioidosis Study has documented 785 melioidosis cases over 23 years. Recurrent melioidosis occurred in 39/679 (5.7%) patients surviving initial infection; 29 patients suffered relapse of the original infection, and 10 presented with a new Burkholderia pseudomallei infection. With improved therapy, relapse has become rare in recent years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.